$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000180422022000023 Filed on August 03, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$2.857B	$2.965B	$4.952B
YoY Change	-44.4%	17.26%	104.37%
Cost Of Revenue	$297.1M	$404.9M	$982.6M
YoY Change	-57.17%	31.46%	178.28%
Gross Profit	$2.560B	$2.560B	$3.969B
YoY Change	-42.4%	15.29%	91.76%
Gross Profit Margin	89.6%	86.34%	80.16%
Selling, General & Admin	$476.3M	$450.0M	$559.6M
YoY Change	14.85%	10.95%	84.38%
% of Gross Profit	18.6%	17.58%	14.1%
Research & Development	$794.3M	$843.8M	$785.6M
YoY Change	11.22%	13.58%	5.52%
% of Gross Profit	31.03%	32.96%	19.79%
Depreciation & Amortization	$74.40M	$74.30M	$74.50M
YoY Change	4.64%	10.24%	20.75%
% of Gross Profit	2.91%	2.9%	1.88%
Operating Expenses	$1.271B	$1.294B	$1.329B
YoY Change	12.55%	12.65%	47.25%
Operating Profit	$1.110B	$1.259B	$2.640B
YoY Change	-66.84%	13.1%	126.2%
Interest Expense	$13.10M	$13.60M	-$151.8M
YoY Change	-9.03%	-6.85%	-420.25%
% of Operating Profit	1.18%	1.08%	-5.75%
Other Income/Expense, Net	-$146.7M	-$197.4M	$15.50M
YoY Change	-136.17%	-240.7%	51.96%
Pretax Income	$963.2M	$1.061B	$2.503B
YoY Change	-74.33%	-15.32%	104.43%
Income Tax	$111.1M	$87.60M	$274.4M
% Of Pretax Income	11.53%	8.26%	10.96%
Net Earnings	$852.1M	$973.5M	$2.229B
YoY Change	-72.5%	-12.71%	93.96%
Net Earnings / Revenue	29.82%	32.83%	45.01%
Basic Earnings Per Share	$7.90	$9.12
Diluted Earnings Per Share	$7.47	$8.61	$19.66M
COMMON SHARES
Basic Shares Outstanding	107.9M shares	106.8M shares
Diluted Shares Outstanding	114.0M shares	113.1M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.566B	$7.051B	$5.695B
YoY Change	93.47%	101.22%	58.76%
Cash & Equivalents	$3.395B	$3.346B	$2.886B
Short-Term Investments	$4.171B	$3.705B	$2.809B
Other Short-Term Assets	$583.6M	$424.9M	$332.4M
YoY Change	31.35%	-40.41%	-43.85%
Inventory	$2.219B	$1.992B	$1.951B
Prepaid Expenses
Receivables	$5.161B	$4.839B	$6.037B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.53B	$14.31B	$14.01B
YoY Change	16.44%	42.28%	43.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.638B	$3.556B	$3.482B
YoY Change	8.31%	9.01%	8.09%
Goodwill
YoY Change
Intangibles			$6.700M
YoY Change
Long-Term Investments	$6.463B	$7.131B	$6.878B
YoY Change	64.03%	98.96%	115.27%
Other Assets	$269.9M	$262.0M	$222.8M
YoY Change	88.87%	79.82%	32.54%
Total Long-Term Assets	$11.68B	$12.04B	$11.42B
YoY Change	43.29%	56.05%	54.65%
TOTAL ASSETS
Total Short-Term Assets	$15.53B	$14.31B	$14.01B
Total Long-Term Assets	$11.68B	$12.04B	$11.42B
Total Assets	$27.21B	$26.35B	$25.43B
YoY Change	26.62%	48.26%	48.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$534.2M	$470.3M	$564.0M
YoY Change	12.23%	-13.39%	18.61%
Accrued Expenses	$1.933B	$2.046B	$2.207B
YoY Change	-4.19%	37.13%	44.99%
Deferred Revenue	$566.3M	$491.3M	$442.0M
YoY Change	8.9%	5.68%	-23.49%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$719.7M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$3.034B	$3.008B	$3.933B
YoY Change	-18.71%	-6.53%	45.79%
LONG-TERM LIABILITIES
Long-Term Debt	$1.981B	$1.980B	$1.980B
YoY Change	0.08%	0.08%	0.08%
Other Long-Term Liabilities	$724.7M	$692.5M	$680.2M
YoY Change	21.53%	21.17%	-1.0%
Total Long-Term Liabilities	$2.705B	$2.673B	$2.660B
YoY Change	5.04%	4.8%	-0.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.034B	$3.008B	$3.933B
Total Long-Term Liabilities	$2.705B	$2.673B	$2.660B
Total Liabilities	$6.518B	$6.434B	$6.666B
YoY Change	2.51%	11.02%	8.6%
SHAREHOLDERS EQUITY
Retained Earnings	$20.79B	$19.94B	$18.97B
YoY Change	37.64%	66.07%	74.13%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.003B	$8.611B	$8.261B
YoY Change	24.67%	24.16%	24.91%
Treasury Stock Shares	20.60M shares	19.94M shares	19.40M shares
Shareholders Equity	$20.69B	$19.91B	$18.77B
YoY Change
Total Liabilities & Shareholders Equity	$27.21B	$26.35B	$25.43B
YoY Change	26.62%	48.26%	48.19%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	$852.1M	$973.5M	$2.229B
YoY Change	-72.5%	-12.71%	93.96%
Depreciation, Depletion And Amortization	$74.40M	$74.30M	$74.50M
YoY Change	4.64%	10.24%	20.75%
Cash From Operating Activities	$564.4M	$2.102B	$2.373B
YoY Change	-9.94%	214.39%	92.73%
INVESTING ACTIVITIES
Capital Expenditures	-$153.6M	-$141.8M	-$154.9M
YoY Change	3.43%	22.98%	-4.03%
Acquisitions
YoY Change
Other Investing Activities	-$260.3M	-$1.564B	-$1.858B
YoY Change	-194.9%	65.68%	1193.73%
Cash From Investing Activities	-$413.9M	-$1.705B	-$2.013B
YoY Change	-429.01%	61.03%	559.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$163.5M
YoY Change		-177.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-101.1M	$64.70M	-906.6M
YoY Change	-14.47%	-117.66%	196.95%
NET CHANGE
Cash From Operating Activities	564.4M	$2.102B	2.373B
Cash From Investing Activities	-413.9M	-$1.705B	-2.013B
Cash From Financing Activities	-101.1M	$64.70M	-906.6M
Net Change In Cash	49.40M	$461.1M	-546.8M
YoY Change	-92.21%	-160.92%	-188.09%
FREE CASH FLOW
Cash From Operating Activities	$564.4M	$2.102B	$2.373B
Capital Expenditures	-$153.6M	-$141.8M	-$154.9M
Free Cash Flow	$718.0M	$2.244B	$2.527B
YoY Change	-7.38%	186.23%	81.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-19034
	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3444607
	dei	Entity Address Address Line1 EntityAddressAddressLine1	777 Old Saw Mill River Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tarrytown
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10591-6707
	dei	City Area Code CityAreaCode	914
	dei	Local Phone Number LocalPhoneNumber	847-7000
	dei	Security12b Title Security12bTitle	Common Stock - par value $.001 per share
	dei	Trading Symbol TradingSymbol	REGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	1887000000	usd
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3395100000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2885600000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4171300000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2809100000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5161400000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6036500000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2218500000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1951300000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	583600000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	332400000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	15529900000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	14014900000	usd
CY2022Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	6415900000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	6838000000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3637700000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3482200000	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1352400000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	876900000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	269900000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	222800000	usd
CY2022Q2	us-gaap	Assets Assets	27205800000	usd
CY2021Q4	us-gaap	Assets Assets	25434800000	usd
CY2022Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	534200000	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	564000000.0	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1933400000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2206800000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	719700000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	566300000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	442000000.0	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3033900000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3932500000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1980700000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1980000000	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	720000000.0	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	58700000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	73300000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	724700000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	680200000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	6518000000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6666000000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9120200000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8087500000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	20793900000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	18968300000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-223800000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26200000	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	20600000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	19400000	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	9002600000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8260900000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20687800000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18768800000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27205800000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25434800000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2857200000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5138500000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5822300000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7667200000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	794300000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	714200000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1638100000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1457100000	usd
CY2022Q2	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	197000000.0	usd
CY2021Q2	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	225100000	usd
	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	476300000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	414700000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	926300000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	820300000	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17400000	usd
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	31300000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	37600000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	71800000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	1747300000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	1791300000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3453900000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3207300000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1109900000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3347200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	2368400000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	4459900000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-133600000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	420000000.0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-317400000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	574900000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	13100000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	14400000	usd
	us-gaap	Interest Expense InterestExpense	26700000	usd
	us-gaap	Interest Expense InterestExpense	29000000.0	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146700000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	405600000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-344100000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	545900000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	963200000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3752800000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2024300000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5005800000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	111100000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	653900000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	198700000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	791700000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	852100000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3098900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1825600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4214100000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.90
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	29.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	17.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	40.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.47
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	27.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	38.07
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107900000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105000000.0	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105200000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114000000.0	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110700000	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	852100000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3098900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1825600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4214100000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-53700000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-800000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-198600000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14100000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	300000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1000000.0	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	500000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	798400000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3098400000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1628000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4200500000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18768800000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	593700000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	105800000	usd
CY2022Q1	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	14500000	usd
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	352000000.0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165900000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-143900000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19914700000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	228000000.0	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	41900000	usd
CY2022Q2	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	16200000	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	393600000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166000000.0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	852100000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-53700000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20687800000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11025300000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	93900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1825600000	usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	66400000	usd
CY2021Q1	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	10000000.0	usd
CY2021Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	323500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4214100000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135600000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13100000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	11977000000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	216600000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	26100000	usd
CY2021Q2	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	14100000	usd
CY2021Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	288600000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135900000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3098900000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-500000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	15127300000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148700000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138500000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	326700000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	276400000	usd
	regn	Marketable And Other Securities Gain Loss MarketableAndOtherSecuritiesGainLoss	-370900000	usd
	regn	Marketable And Other Securities Gain Loss MarketableAndOtherSecuritiesGainLoss	553900000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-138300000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-192600000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	381000000.0	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-51800000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	195000000.0	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-875100000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2883900000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	328700000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	221500000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	288500000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	277800000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	109700000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-64800000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-325700000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	423700000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	840500000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-2918900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2666100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1295200000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3774900000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1886500000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2181400000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1217100000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	295400000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	263800000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	230300000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2119200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-933200000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	828400000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	308200000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	147700000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	180700000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	717100000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	612100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-36400000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-484600000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	510500000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-122600000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2898100000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2207300000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3408600000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2084700000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	852100000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3098900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	1825600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4214100000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107900000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105000000.0	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105200000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114000000.0	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110700000	shares
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	40000000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.90
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	29.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	17.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	40.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.47
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	27.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	38.07
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9994400000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	100000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	282400000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9712100000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8428700000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10800000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42300000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8397200000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	6516300000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	4171200000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	2809100000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	5540900000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	5588100000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9712100000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8397200000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	9134000000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	263100000	usd
CY2022Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	1513000000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	281100000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	19300000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	9415100000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	282400000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	42300000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	6516300000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	42300000	usd
CY2022Q2	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-163700000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-374900000	usd
CY2021Q2	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	409000000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	552900000	usd
CY2022Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	47300000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	831700000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	721900000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	717300000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	707200000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	45600000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	73700000	usd
CY2022Q2	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	623900000	usd
CY2021Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	448500000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2218500000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1951300000	usd
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	19200000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	66600000	usd
CY2021Q2	us-gaap	Inventory Write Down InventoryWriteDown	139900000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	149300000	usd
CY2022Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
	us-gaap	Lessee Finance Lease Option To Extend LesseeFinanceLeaseOptionToExtend	five-year
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.115
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.174
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.098
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.158
CY2022Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	700000	shares
CY2021Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	600000	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1200000	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1300000	shares
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	393600000	usd
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	288600000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	745500000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	612100000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3395100000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2072200000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	13500000	usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	12500000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3408600000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2084700000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	81900000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	74800000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	93400000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	83600000	usd

Files In Submission

Name	View Source	Status
0001804220-22-000023-index-headers.html	Edgar Link	pending
0001804220-22-000023-index.html	Edgar Link	pending
0001804220-22-000023.txt	Edgar Link	pending
0001804220-22-000023-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-20220630.htm	Edgar Link	pending
regn-20220630.xsd	Edgar Link	pending
regn-20220630_cal.xml	Edgar Link	unprocessable
regn-20220630_def.xml	Edgar Link	unprocessable
regn-20220630_htm.xml	Edgar Link	completed
regn-20220630_lab.xml	Edgar Link	unprocessable
regn-20220630_pre.xml	Edgar Link	unprocessable
regn-ex_101x6302022x10q.htm	Edgar Link	pending
regn-ex_102x06302022x10q.htm	Edgar Link	pending
regn-ex_103x6302022x10q.htm	Edgar Link	pending
regn-ex_311x06302022x10q.htm	Edgar Link	pending
regn-ex_312x06302022x10q.htm	Edgar Link	pending
regn-ex_32x06302022x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2022 Q2 Form 10-Q Financial Statement

#000180422022000023 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2022 Q2 Form 10-Q Financial Statement

#000180422022000023 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn